ADVFN - Advanced Financial Network.
HOME» NYSE » V » VRX Stock Price » VRX Stock News

Valeant Pharma Share News

 Valeant Pharmaceuticals International Stock Price
VRX Stock Price
 Valeant Pharmaceuticals International Stock Chart
VRX Stock Chart
 Valeant Pharmaceuticals International Stock News
VRX Stock News
 Valeant Pharmaceuticals International Company Information
VRX Company Information
 Valeant Pharmaceuticals International Stock Trades
VRX Stock Trades

CORRECT(12/13): FDA Panel Recommends Use Of Alexza Pharma's Bipolar Treatment

("FDA Panel Recommends Use Of Alexza Pharma's Bipolar Treatment" on Dec. 13 and an earlier story on Jan. 18 misstated that Valeant Pharmaceuticals International Inc. is currently a commercial partner for the drug. A corrected version follows:) DOW JONES NEWSWIRES Alexza Pharmaceuticals Inc. (ALXA) said a U.S. Food and Drug Administration panel has recommended that its schizophrenic and bipolar disorder treatment be approved for use. Shares were recently up 76% to $1.10 as the company's chief executive called the panel's recommendation "another step forward" for the drug's development. Alexza in August said it refiled its new drug application for the treatment, adding new data and sections that aimed to address safety concerns raised by the agency last year. "If approved, we believe Adasuve represents a valuable treatment option for patients and physicians alike. We look forward to continuing to work toward our goal of bringing Adasuve to market in 2012," said Chief Executive Thomas B. King. Alexza last month reported its third-quarter loss widened sharply from a year earlier as it recorded higher research and development expenses and a loss on a contingent liability. -By Mia Lamar, Dow Jones Newswires; 212-416-3207; mia.lamar@dowjones.com

Stock News for Valeant Pharma (VRX)
DateTimeHeadline
08/27/201516:35:25Statement of Changes in Beneficial Ownership (4)
08/25/201516:48:25Statement of Changes in Beneficial Ownership (4)
08/25/201508:40:45Current Report Filing (8-k)
08/25/201508:00:00Valeant Pharmaceuticals Announces The Addition Of D. Robert Hale...
08/25/201508:00:00Valeant Pharmaceuticals Announces The Addition Of D. Robert Hale...
08/20/201507:28:00Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals
08/20/201507:28:00Valeant Pharmaceuticals To Acquire Sprout Pharmaceuticals
08/14/201514:19:16Bernie Sanders, Elijah Cummings Question Valeant on Heart-Drug...
08/10/201509:15:00Active Equities to Watch in the Healthcare Sector -- AstraZeneca...
08/10/201509:10:21Endo International Beats Revenue, Earnings Targets
08/06/201509:10:27Activist Ackman Takes $5.5 Billion Stake in Snacks Giant Mondelez
08/05/201509:30:07Allergan Changes Deal for Kythera
08/03/201516:55:24Statement of Changes in Beneficial Ownership (4)
07/30/201501:00:00Pharming Reports on Financial Results First Half Year 2015
07/28/201506:06:27Quarterly Report (10-q)
07/26/201521:52:43Teva Poised to Get a Big Boost in Generics
07/23/201507:30:08Valeant Upgrades Views With Big Quarter
07/23/201506:15:19Current Report Filing (8-k)
07/23/201506:00:00Valeant Pharmaceuticals Reports Second Quarter 2015 Financial...
07/23/201506:00:00Valeant Pharmaceuticals Reports Second Quarter 2015 Financial...

Valeant Pharma and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad